Cilostazol

西洛他唑

Report date: 2026/04/16 20:00:17
NMEFirst In Class

Base Information

Drug NameCilostazol
Drug Alias NameCilostazolum西斯他唑PletalPletaalOPC-13013 +[6
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphodiesterase 3 inhibitors
TargetsPhosphodiesterase 3
Therapy Area/IndicationsContraceptionIschemic StrokeWounds and Injuries +[25
Global Approved IndicationsIntermittent ClaudicationArterial Occlusive Diseases
Approved Indications in ChinaArterial Occlusive Diseases
Original Approved Country/TerritoryJapan
Original Approved Date1988/01/20
Country/TerritoryCanadaUnited StatesTaiwan +[10
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesOtsuka Holdings Co Ltd
China Registration ClassN/A

Develop Information

Active IndicationsIschemic StrokeWounds and InjuriesIntermittent Claudication +[15
Inactive IndicationsContraceptionPainPeripheral Vascular Diseases +[10

Other Information

ATC CodeB01AC23